Date:November 29, 2023
Your Name:Linna Shi
Manuscript Title:_Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with
pathological parameters and prognosis
Manuscript number (if known):TAU-20-970

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	√ _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√ _None	
3	Royalties or licenses	√ _None	
4	Consulting fees	√_None	

5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_√_None	
	testimony		
7	Support for attending meetings and/or travel	_ √ _None	
8	Patents planned, issued or	_√_None	
	pending		
9	Participation on a Data	_√_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
12	Receipt of equipment,	_√_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_√_None	
	financial interests		

No conflicts of interest		

Please place an "X" next to the following statement to indicate your agreement:

Date:November 29, 2023
Your Name:Ruihua Lv
Manuscript Title:_Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with
pathological parameters and prognosis
Manuscript number (if known):TAU-20-970

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	√ _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ √ _None	
3	Royalties or licenses	√_None	
4	Consulting fees	√_None	

5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_√_None	
	testimony		
7	Support for attending meetings and/or travel	_ √ _None	
8	Patents planned, issued or	_ √ _None	
	pending		
9	Participation on a Data	_√_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
12	Receipt of equipment,	_√_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_√_None	
	financial interests		

No conflicts of interest		

Please place an "X" next to the following statement to indicate your agreement:

Date:November 29, 2023
Your Name: Chen Li
Manuscript Title:_Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with
pathological parameters and prognosis
Manuscript number (if known):TAU-20-970

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	√ _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√_None	
3	Royalties or licenses	_ √ _None	
4	Consulting fees	√_None	

5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_√_None	
	testimony		
7	Support for attending meetings and/or travel	_ √ _None	
8	Patents planned, issued or	_ √ _None	
	pending		
9	Participation on a Data	_√_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
12	Receipt of equipment,	_√_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_√_None	
	financial interests		

No conflicts of interest		

Please place an "X" next to the following statement to indicate your agreement:

Date:November 29, 2023
Your Name: Dong Han
Manuscript Title:_Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with
pathological parameters and prognosis
Manuscript number (if known):TAU-20-970

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	√ _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√ _None	
3	Royalties or licenses	√ _None	
4	Consulting fees	√_None	

5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_√_None	
	testimony		
7	Support for attending meetings and/or travel	_ √ _None	
8	Patents planned, issued or	_ √ _None	
	pending		
9	Participation on a Data	_√_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
	·		
12	Receipt of equipment,	_√_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_√_None	
	financial interests		

No conflicts of interest		

Please place an "X" next to the following statement to indicate your agreement:

Date:November 29, 2023
Your Name: Zhanli Ren
Manuscript Title:_Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with
pathological parameters and prognosis
Manuscript number (if known):TAU-20-970

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	√ _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√_None	
3	Royalties or licenses	√_None	
4	Consulting fees	√_None	

5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_√_None	
	testimony		
7	Support for attending meetings and/or travel	_ √ _None	
8	Patents planned, issued or	_ √ _None	
	pending		
9	Participation on a Data	_√_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
	·		
12	Receipt of equipment,	_√_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_√_None	
	financial interests		

No conflicts of interest		

Please place an "X" next to the following statement to indicate your agreement:

Date:November 29, 2023
Your Name:Ge Ren
Manuscript Title:_Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with
pathological parameters and prognosis
Manuscript number (if known):TAU-20-970

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_ \dark_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√_None	
3	Royalties or licenses	_ √ _None	
4	Consulting fees	√_None	

5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_√_None	
	testimony		
7	Support for attending meetings and/or travel	_ √ _None	
8	Patents planned, issued or	_ √ _None	
	pending		
9	Participation on a Data	_√_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
12	Receipt of equipment,	_√_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_√_None	
	financial interests		

No conflicts of interest		

Please place an "X" next to the following statement to indicate your agreement: